GENFIT: ordinary and extraordinary SHAREHOLDERS' meeting of june 15, 2018 - AVAILABILITY OF PREPARATORY DOCUMENTS
Lille (France), Cambridge (Massachusetts, United States), May 9, 2018 - GENFIT (Euronext: GNFT - ISIN: FR0004163111), a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions in metabolic and inflammatory diseases, that notably affect the liver or the gastrointestinal system, today announced the that it has published today in today's French legal announcements bulletin (Bulletin des Annonces Légales Obligatoires) its convening notice to the Ordinary and Extraordinary Shareholders' Meeting to be held on Friday, June on June 15, 2018, at 2:30pm, at the Faculty of Pharmaceutical & Biological Sciences of Lille, located Parc Eurasanté, 3 rue du Professeur Laguesse, 59000 Lille, France.
All documentation regarding this Shareholders' Meeting is available to shareholders in accordance with existing regulations, and is available on the Company's website, in the documentation center (http://www.genfit.com/investors/documentation-center/).
Documents listed in Article R.225-83 of the French commercial code are available to shareholders in accordance with existing regulations.
For this 2018 Ordinary and Extraordinary Shareholders' Meeting, the Company will allow shareholders to send their voting instructions via Internet through the VOTACCESS platform. The Company has made available in the documentation center of its website a tutorial to familiarize its shareholders with this new tool for online voting.
More generally, shareholders are invited to contact the toll-free (France only) number starting Monday, May 14, 2018, with any questions regarding how to participate in the Meeting: 0800 940 651
About GENFIT
GENFIT is a biopharmaceutical company focused on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatment and an increasing number of patients worldwide. GENFIT's R&D efforts are focused on bringing new medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver (such as NASH - Nonalcoholic steatohepatitis) and more generally the gastro-intestinal arena. GENFIT's approach combines novel treatments and biomarkers. Its lead proprietary compound, elafibranor, is currently in a Phase 3 study. With facilities in Lille and Paris, France, and Cambridge, MA (USA), the Company has approximately 130 employees. GENFIT is a public company listed in compartment B of Euronext's regulated market in Paris (Euronext: GNFT - ISIN: FR0004163111). www.genfit.com
Forward Looking Statement / Disclaimer
This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, including related to biomarkers, progression of, and results of clinical data from, the RESOLVE-IT trial and the trial of elafibranor in PBC, review and approvals by regulatory authorities, such as the FDA or the EMA, regarding in particular, elafibranor in NASH and PBC, as well as other drug candidates in other indications and biomarkers candidates, the success of any inlicensing strategies, the Company's continued ability to raise capital to fund its development, as well as those discussed or identified in the Company's public filings with the AMF, including those listed under Section 4 "Main Risks and Uncertainties" of the Company's 2017 Registration Document registered with the French Autorité des marchés financiers on April 27, 2018 under n° R.18-032, which is available on GENFIT's website (www.genfit.com) and on the website of the AMF (www.amf-france.org). Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements. This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in GENFIT in any country. This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall supersede.
CONTACT
GENFIT | Jean-François Mouney - Chairman & CEO | +333 2016 4000
PRESS RELATIONS | Bruno Arabian | +336 8788 4726
